CU20180025A7 - Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue - Google Patents

Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue

Info

Publication number
CU20180025A7
CU20180025A7 CU2018000025A CU20180025A CU20180025A7 CU 20180025 A7 CU20180025 A7 CU 20180025A7 CU 2018000025 A CU2018000025 A CU 2018000025A CU 20180025 A CU20180025 A CU 20180025A CU 20180025 A7 CU20180025 A7 CU 20180025A7
Authority
CU
Cuba
Prior art keywords
dengue virus
preparation
against dengue
tetravalent vaccine
tetravalent
Prior art date
Application number
CU2018000025A
Other languages
English (en)
Other versions
CU24579B1 (es
Inventor
Neuza Maria Frazatti Gallina
Original Assignee
Fund Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Butantan filed Critical Fund Butantan
Publication of CU20180025A7 publication Critical patent/CU20180025A7/es
Publication of CU24579B1 publication Critical patent/CU24579B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>Proceso para preparar una vacuna tetravalente atenuada contra el virus del dengue y producto del mismo. La presente invención también se refiere a un proceso de preparación de una vacuna tetravalente contra el dengue para su administración a un sujeto, a un método para inducir una respuesta inmune contra los serotipos 1, 2, 3 y 4 del virus del dengue en un paciente y a un kit para una vacuna tetravalente contra el dengue.</p>
CU2018000025A 2015-09-08 2016-09-06 Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue CU24579B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/847,422 US10004795B2 (en) 2015-09-08 2015-09-08 Process for preparing an attenuated tetravalent dengue vaccine
PCT/BR2016/050224 WO2017041156A1 (en) 2015-09-08 2016-09-06 Process for preparing an attenuated tetravalent dengue vaccine

Publications (2)

Publication Number Publication Date
CU20180025A7 true CU20180025A7 (es) 2018-11-06
CU24579B1 CU24579B1 (es) 2022-02-04

Family

ID=56268413

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000025A CU24579B1 (es) 2015-09-08 2016-09-06 Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue

Country Status (17)

Country Link
US (2) US10004795B2 (es)
EP (1) EP3347043A1 (es)
JP (1) JP6968070B2 (es)
CN (1) CN108289945B (es)
AR (1) AR105966A1 (es)
AU (1) AU2016318349B2 (es)
BR (1) BR102015030332B1 (es)
CL (1) CL2018000609A1 (es)
CO (1) CO2018003451A2 (es)
CR (1) CR20180202A (es)
CU (1) CU24579B1 (es)
EC (1) ECSP18026090A (es)
HK (1) HK1258584A1 (es)
MX (2) MX2018002901A (es)
PE (1) PE20181135A1 (es)
TW (1) TWI733694B (es)
WO (1) WO2017041156A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913435TA (en) 2013-03-15 2020-03-30 Takeda Vaccines Inc Compositions and methods for dengue virus chimeric constructs in vaccines
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
EA202090967A1 (ru) 2017-10-16 2020-08-12 Серум Инститьют Оф Индия Прайват Лимитед Стабильные составы вакцин, включающих, в частности, живой аттенуированный рекомбинантный флавивирус, и процесс их приготовления
JP7042341B2 (ja) 2017-12-07 2022-03-25 メルク・シャープ・アンド・ドーム・コーポレーション デングウイルスワクチン組成物の製剤
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
IL281177B2 (en) 2018-09-05 2024-03-01 Takeda Vaccines Inc Dengue fever vaccine unit dose and its administration
WO2023044774A1 (en) * 2021-09-24 2023-03-30 Sichuan Clover Biopharmaceuticals, Inc. Tpo mimetic fusion proteins and methods of use submission of sequence listing as ascii text file

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1554301T1 (sl) * 2002-05-03 2011-01-31 Us Health VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE
GB0304799D0 (en) * 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
AU2004312352B2 (en) * 2003-12-19 2010-08-19 Wyeth Serum-free vero cell banking process
WO2006066332A1 (en) * 2004-12-23 2006-06-29 Murray Goulburn Co-Operative Co Limited Method of manufacture of a modified milk powder suitable as a rennet casein extender or replacer
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
SG10201913435TA (en) * 2013-03-15 2020-03-30 Takeda Vaccines Inc Compositions and methods for dengue virus chimeric constructs in vaccines
WO2015048744A2 (en) * 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine

Also Published As

Publication number Publication date
JP6968070B2 (ja) 2021-11-17
BR102015030332A2 (pt) 2016-07-05
MX2021013109A (es) 2021-11-17
WO2017041156A1 (en) 2017-03-16
US20180256702A1 (en) 2018-09-13
CN108289945B (zh) 2022-05-31
CN108289945A (zh) 2018-07-17
PE20181135A1 (es) 2018-07-17
CO2018003451A2 (es) 2018-11-30
HK1258584A1 (zh) 2019-11-15
US10004795B2 (en) 2018-06-26
MX2018002901A (es) 2018-09-18
US10201600B2 (en) 2019-02-12
AU2016318349B2 (en) 2019-10-17
AR105966A1 (es) 2017-11-29
TWI733694B (zh) 2021-07-21
EP3347043A1 (en) 2018-07-18
TW201718008A (zh) 2017-06-01
CU24579B1 (es) 2022-02-04
CL2018000609A1 (es) 2018-08-17
BR102015030332B1 (pt) 2019-11-05
JP2018527408A (ja) 2018-09-20
CR20180202A (es) 2018-08-10
US20170065701A1 (en) 2017-03-09
AU2016318349A1 (en) 2018-04-19
ECSP18026090A (es) 2018-10-31

Similar Documents

Publication Publication Date Title
CU20180025A7 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
MX2018007627A (es) Vacuna contra el virus del zika.
ECSP18001613A (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
PH12018500127A1 (en) Vaccine compositions
EP4233898A3 (en) Influenza mrna vaccines
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
IL259451A (en) Live virus with accumulation of dengue fever of a weakened nature and vaccination of dengue fever containing identical antigens